COVID-19 vaccine effectiveness
(Randomized evidence)

Analyses are updated every Friday

Methods

Variants of concern

RCTs

Vaccine types

Overall results (Last update:2021-10-22)

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04510207, ChiCTR2000034780
Sinopharm - China National Biotec Group Company Limited
Al Kaabi N, JAMA, 2021

Full text
Commentary
Commentary
Inactivated virus

WIV04

HBO2

Placebo

RCT
Phase 3
Healthy adults free of known COVID-19 or HIV infection at 3 centres in United Arab Emirates and Bahrain N=40411
Some concerns
Details

Full description

NCT04651790
Sinovac Research and Development Co., Ltd
Bueno S, Clin Infect Dis, 2021

Full text
Commentary
Commentary
Inactivated virus

CoronaVac

Placebo

RCT
Phase 3
Adult healthcare workers with no history of confirmed symptomatic SARS-CoV-2 infection who were in contact with possible or confirmed cases of COVID-19 in 8 sites in Chile. N=434
Some concerns
Details

Full description

NCT04412538
Institute of Medical Biology (IMB), Chinese Academy of Medical Sciences (CAMS).
Che Y, Clin Infect Dis, 2020

Full text
Commentary
Inactivated virus

KMS-1 100 EU D0/14

KMS-1 150 EU D0/14

KMS-1 100 EU D0/28

KMS-1 150 EU D0/28

Placebo

RCT
Phase 2
Healthy SARS-CoV-2 serology/DNA negative adults in two centres in China N=750
Some concerns
Details

Full description

NCT04641481
Bharat Biotech
Ella R, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

BBV152

Placebo

RCT
Phase 3
Adults with no history of SARS-CoV-2 infection who were healthy or had stable chronic medical conditions at 25 centers in India N=25778
Some concerns
Details

Full description

NCT04471519
Bharat Biotech
Ella R, Lancet Infect Dis, 2021

Full text
Commentary
; Commentary
Inactivated virus

BBV152

3mcg BBV152 + Algel-IMDG

RCT
Phase 2
Healthy adults (<65 yo) and children (≥12 yo)volunteers, SARS-CoV-2 infection-free in 9 centres in India N=380
Some concerns
Details

Full description

NCT04471519
Bharat Biotech
Ella R, Lancet Infect Dis, 2021

Full text
Commentary
Inactivated virus

BBV152 3mcg + Algel-IMDG

BBV152

BBV152

Placebo

RCT
Phase 1
Healthy SARS-CoV-2 serology/PCR negative adults in 11 centres in India N=375
Low
Details

Full description

ChiCTR2100041705, ChiCTR2100041706
Sinopharm + China National Biotec Group + Beijing Institute of Biological Products
Feng Y, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

BBIBP-CorV D0/14

BBIBP-CorV D0/21

BBIBP-CorV D0/28

RCT
*
Healthy adults from high-risk occupational population at a single center in China N=809
Some concerns
Details

Full description

ChiCTR2000031809
Sinopharm + China National Biotec Group Co + Wuhan Institute of Biological Products
Guo W, EClinicalMedicine, 2021

Full text
Commentary
Inactivated virus

Inactivate2.5mcg D0/28/56

Inactivate 5mcg D0/28/56

Inactivate10mcg D0/28/56

Inactivated 5 mcg D0/14

Inactivate 5 mcg D0/21

Inactivate 5 mcg D0/28

Inactivate2.5mcg D0/28/56

Placebo

Placebo

Placebo

Placebo

Placebo

Placebo

Placebo

RCT
Phase 1-2
Healthy adults with no history of COVID-19 at 5 centers in China. N=1120
Some concerns
Details

Full description

NCT04551547
Sinovac Research and Development Co., Ltd
Han B, SSRN, 2021

Full text
Commentary
Commentary
Inactivated virus

CoronaVac 1.5 mcg D0/28

Placebo

CoronaVac

RCT
Phase 1/2
Healthy children and adolescents aged 3-17 years with no history of SARS-CoV-2 infection in a single centre in China. N=552
Low
Details

Full description

NCT04671017; ISRCTN 82411169
Valneva Austria GmbH + National Institute for Health Research, UK
Lazarus R, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

VL A2001 3AU

VL A2001 3AU

VL A2001 35AU

VL A2001 7AU

RCT
Phase 1-2
Healthy adult volunteers aged 18-55 at 4 centers in the UK N=153
Some concerns
Details

Full description

NCT04383574
Sinovac Research and Development Co., Ltd.
Li M, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

CoronaVac

CoronaVac 1.5 mcg

Placebo

RCT
Phase 2
Healthy adults aged ≥60 years with no known history of COVID-19 or recent exposure in a single center in China. N=350
Some concerns
Details

Full description

NCT04456595
Sinovac Research and Development Co., Ltd
Palacios R, SSRN, 2021
PROFISCOV

Full text
Commentary
Inactivated virus

CoronaVac

Placebo

RCT
Phase 3
Healthcare professionals with or without previous COVID-19 infection caring for COVID-19 patients at 16 centers in Brazil. N=12408
Some concerns
Details

Full description

NCT04756323, ChiCTR2000039462
Shenzhen Kangtai Biological Products and Beijing Minhai Biotechnology
Pan HX, Chin Med J, 2021

Full text
Commentary
Inactivated virus

KCONVAC 5mcg D0/14

KCONVAC 5mcg D0/14

KCONVAC 5mcg D0/28

KCONVAC 5mcg D0/28

KCONVAC 5mcg D0/14

KCONVAC 10mcg D0/14

KCONVAC 10mcg D0/14

KCONVAC 5mcg D0/14

KCONVAC 10mcg D0/28

Placebo

Placebo

Placebo

RCT
Phase 2
Healthy adult volunteers with no history of COVID-19 and HIV- and SARS-CoV-2 infection-free in a single centre in China. N=500
Low
Details

Full description

NCT04758273, ChiCTR2000038804
Shenzhen Kangtai Biological Products and Beijing Minhai Biotechnology
Pan HX, Chin Med J, 2021

Full text
Commentary
Inactivated virus

5mcg KCONVAC

10mcg KCONVAC

RCT
Phase 1
Healthy adult volunteers with no history of COVID-19 and HIV- and SARS-CoV-2 infection-free in a single centre in China. N=60
Low
Details

Full description

NCT04764422
The Government Pharmaceutical Organization (GPO); PATH; Dynavax
Pitisuttithum P, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

NDV-HXP-S 1mcg

NDV-HXP-S 1mcg + CpG1018

NDV-HXP-S 3mcg

NDV-HXP-S 3mcg + CpG1018

NDV-HXP-S 10mcg

Placebo

RCT
Phase 1
Healthy adults without immunosuppression negative for SARS-CoV-2 antibodies at a single center in Thailand N=210
Some concerns
Details

Full description

NCT04412538
The Institute of Medical Biology (IMB), Chinese Academy of Medical Sciences (CAM
Pu J, Vaccine, 2021

Full text
Commentary
Inactivated virus

KMS-1 100 EU D0/14

KMS-1 100 EU D0/28

Placebo

RCT
Phase 1
Healthy adults aged 18 to 59 years, SARS-CoV-2 nucleic acid or antibodies negative in a single centre in China N=192
Some concerns
Details

Full description

NCT04582344
Sinovac Research and Development Co., Ltd
Tanriover M, Lancet , 2021

Full text
Commentary
Commentary
Inactivated virus

CoronaVac

Placebo

RCT
Phase 3
Healthy healthcare workers and adults aged 18–59 years with no history of COVID-19 from 24 centres in Turkey N=10218
Some concerns
Details

Full description

NCT04383574
Sinovac Research and Development Co., Ltd
Wu Z, Lancet Infect Dis, 2021

Full text
Commentary
; Commentary
Inactivated virus

CoronaVac 1.5mcg D0/28

CoronaVac

CoronaVac 6mcg D0/28

Placebo

RCT
Phase 1/2
Healthy adults aged 60 years and older with no history of SARS-CoV-2 infection in a single centre in China N=422
Low
Details

Full description

ChiCTR2000031809
Wuhan Institute of Biological Products Co Ltd./Sinopharm
Xia S, JAMA, 2020

Full text
Commentary
Inactivated virus

Inactivated 2.5mcg-3doses

Inactivated 5mcg-3doses

Inactivated 10mcg-3doses

Placebo

RCT
Phase 1
Healthy adults, aged 18 to 59 years, without history ofSARS-CoV(via on-site inquiry) or SARS-CoV-2 infection (via serologicaland nucleic acid test N=96
Low
Details

Full description

ChiCTR2000031809
Wuhan Institute of Biological Products Co Ltd./Sinopharm
Xia S, JAMA, 2020
Updated

Full text
Commentary
Inactivated virus

Inactivated 5mcg-D0/14

Inactivated 5mcg-D0/21

Placebo

RCT
Phase 2
Healthy adults, aged 18 to 59 years, without history ofSARS-CoV(via on-site inquiry) or SARS-CoV-2 infection (via serologicaland nucleic acid test N=224
Low
Details

Full description

ChiCTR2000032459
Beijing Institute of Biological Products/Sinopharm
Xia S, Lancet Infect Dis, 2020

Full text
Commentary
Inactivated virus

BBIBP-CorV 8mcg once

BBIBP-CorV 4mcg D0/14

BBIBP-CorV 4mcg D0/21

BBIBP-CorV 4mcg D0/28

Placebo

RCT
Phase 2
Healthy SARS-CoV-2 serology negative adults 18-59 years old and ≥60 years old in a single centre in China N=448
Some concerns
Details

Full description

ChiCTR2000032459
Sinopharm + China Biotec Group Co + Beijing Istitute of Biological Products
Xia S , Lancet, 2021
New

Full text
Commentary
Inactivated virus

BBIBP-CorV 2 mcg

BBIBP-CorV 4 mcg

BBIBP-CorV 2 mcg

Adjuvant

Adjuvant

BBIBP-CorV 2 mcg

RCT
Phase 1-2
Healthy children and adolescents aged 3 to 17 years free from SARS-CoV-2 infection and antibodies at a single centre in China N=1008
Low
Details

Full description

NCT04530357
Research Institute for Biological Safety Problems, Rep of Kazakhstan
Zakarya K, EClinicalMedicine, 2021

Full text
(21)00358-8/fulltextCommentary
Inactivated virus

QazCovid-in D1/21

Placebo

RCT
Phase 1
Healthy adults with no history of COVID-19 that tested negative for SARS-CoV-2 and HIV virus at a single centre in Kazakhstan. N=44
Some concerns
Details

Full description

NCT04530357
Research Institute for Biological Safety Problems, Rep of Kazakhstan
Zakarya K,, EClinicalMedicine, 2021

Full text
(21)00358-8/fulltextCommentary
Inactivated virus

QazCovid-in D1/21

QazCovid-in D1

RCT
Phase 2
Healthy adults with no history of COVID-19 that tested negative for SARS-CoV-2 and HIV virus at a single centre in Kazakhstan. N=200
Some concerns
Details

Full description

NCT04352608
Sinovac Research and Development Co., Ltd
Zhang Y, Lancet Infect Dis, 2020

Full text
Commentary
; Commentary
Inactivated virus

CoronaVac

CoronaVac 6 mcg D0/14

CoronaVac

CoronaVac 6 mcg D0/28

Placebo

RCT
Phase 2
Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China N=600
Some concerns
Details

Full description

NCT04352608
Sinovac Research and Development Co., Ltd
Zhang Y, Lancet Infect Dis, 2020

Full text
Commentary
; Commentary
Inactivated virus

CoronaVac 6 mcg D0/28

CoronaVac 3 mcg D0/28

CoronaVac 6 mcg D0/14

CoronaVac

Placebo

RCT
Phase 1
Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China N=144
Some concerns
Details

Full description